$0.38
-0.015[-3.80%]
At close: Apr 24
$0.38
0[0.00%]
After Hours: 5:01PM EDT
Kazia Therapeutics
(NASDAQ:KZIA)Kazia Therapeutics Stock (NASDAQ:KZIA), Analyst Ratings, Price Targets, Predictions
Kazia Therapeutics Ltd has a consensus price target of $6.67, established from looking at the 4 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Maxim Group, and HC Wainwright & Co. on April 11, 2023, August 2, 2022, and August 2, 2022. With an average price target of $0.67 between HC Wainwright & Co., Maxim Group, and HC Wainwright & Co., there's an implied 75.44% upside for Kazia Therapeutics Ltd from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Maxim Group
Maxim Group
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Kazia Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/11/2023 | KZIA | Buy Now | Kazia Therapeutics | $0.38 | 426.32% | HC Wainwright & Co. | Sean Lee | → $2 | Upgrade | Neutral → Buy | Get Alert |
| 08/02/2022 | KZIA | Buy Now | Kazia Therapeutics | $0.38 | — | Maxim Group | Jason McCarthy | — | Downgrade | Buy → Hold | Get Alert |
| 08/02/2022 | KZIA | Buy Now | Kazia Therapeutics | $0.38 | — | HC Wainwright & Co. | Sean Lee | — | Downgrade | Buy → Neutral | Get Alert |
| 10/14/2021 | KZIA | Buy Now | Kazia Therapeutics | $0.38 | 4636.84% | Maxim Group | Naureen Quibria | — | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Kazia Therapeutics (KZIA)?
The latest price target for Kazia Therapeutics (NASDAQ: KZIA) was reported by HC Wainwright & Co. on April 11, 2023. The analyst firm set a price target for $2.00 expecting KZIA to rise to within 12 months (a possible 426.32% upside). 0 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Kazia Therapeutics (KZIA)?
The latest analyst rating for Kazia Therapeutics (NASDAQ: KZIA) was provided by HC Wainwright & Co., and Kazia Therapeutics upgraded their buy rating.
When was the last upgrade for Kazia Therapeutics (KZIA)?
The last upgrade for Kazia Therapeutics Ltd happened on April 11, 2023 when HC Wainwright & Co. raised their price target to $2. HC Wainwright & Co. previously had a neutral for Kazia Therapeutics Ltd.
When was the last downgrade for Kazia Therapeutics (KZIA)?
The last downgrade for Kazia Therapeutics Ltd happened on August 2, 2022 when Maxim Group changed their price target from N/A to N/A for Kazia Therapeutics Ltd.
When is the next analyst rating going to be posted or updated for Kazia Therapeutics (KZIA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kazia Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kazia Therapeutics was filed on April 11, 2023 so you should expect the next rating to be made available sometime around April 11, 2024.
Is the Analyst Rating Kazia Therapeutics (KZIA) correct?
While ratings are subjective and will change, the latest Kazia Therapeutics (KZIA) rating was a upgraded with a price target of $0.00 to $2.00. The current price Kazia Therapeutics (KZIA) is trading at is $0.38, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.